Sarissa Capital Management

660 Steamboat Road
Greenwich, CT 6830

Website: sarissacap.com

Firm Size

• Assets Under Management (AUM):$907 Million
• Number of Funds:5
• Employees:10
• Firm Type:Hedge Fund

Description

Sarissa Capital Management LP is a hedge fund located in Greenwich, CT. The firm specializes in healthcare investments and was founded by Alex Denner in 2012. Sarissa Capital focuses on investing in pharmaceutical, biotech, and medical device companies. They employ an event-driven investment strategy, seeking opportunities in companies undergoing significant corporate events such as mergers, acquisitions, or regulatory changes. By analyzing the potential outcomes and impact of these events, Sarissa Capital aims to generate alpha for their investors. The firm takes an active approach to its investments, often engaging with management teams and shareholders to unlock value and drive operational improvements within portfolio companies. They believe in long-term capital appreciation and aim to create value through strategic initiatives like asset sales, licensing deals, or management changes. Led by its founder Alex Denner, who has an extensive background in the healthcare industry and was previously a well-known biotech analyst, Sarissa Capital has established itself as a reputable player in the sector. The firm manages a range of assets including private funds and separate accounts for institutional investors. In summary, Sarissa Capital Management LP is a Greenwich-based hedge fund that specializes in healthcare investments. With a focus on event-driven strategies and active engagement with portfolio companies, the firm aims to create value for its investors in the dynamic healthcare industry.

Latest News

Powered by

Jun 29, 2023: Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders
Alkermes plc (Nasdaq: ALKS) (the Company) today announced that, at the Company's 2023 Annual General Meeting of Shareholders (the Annual Meeting), shareholders voted to re-elect all seven of Alkermes' director nominees – Emily Peterson Alva , Shane M. Cooke , Richard B. Gaynor , M.D., Cato T. Laurencin , M.D., Ph.D., Brian P. McKeon , Richard F. Pops and Christopher I. Wright , M.D., Ph.D. Sarissa Capital Management LP nominees Alexander Denner , Ph.D., Patrice Bonfiglio and Sarah Schlesinger , M.D. failed to achieve the necessary votes for election. Additionally, all other Company proposals were approved by shareholders.